Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Recommendation of “Moderate Buy” from Analysts

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has been given a consensus recommendation of “Moderate Buy” by the twenty brokerages that are currently covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a hold recommendation, ten have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $49.94.

A number of analysts recently weighed in on APLS shares. Evercore ISI upgraded shares of Apellis Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, October 31st. Scotiabank decreased their target price on shares of Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating for the company in a research note on Wednesday, November 6th. Needham & Company LLC dropped their price target on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. The Goldman Sachs Group cut Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 price objective for the company. in a research report on Tuesday. Finally, HC Wainwright dropped their target price on Apellis Pharmaceuticals from $83.00 to $57.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Envestnet Asset Management Inc. lifted its holdings in shares of Apellis Pharmaceuticals by 42.2% in the second quarter. Envestnet Asset Management Inc. now owns 134,536 shares of the company’s stock valued at $5,161,000 after purchasing an additional 39,931 shares in the last quarter. Profund Advisors LLC lifted its position in shares of Apellis Pharmaceuticals by 90.7% in the second quarter. Profund Advisors LLC now owns 42,968 shares of the company’s stock valued at $1,648,000 after acquiring an additional 20,435 shares in the last quarter. Algert Global LLC boosted its stake in shares of Apellis Pharmaceuticals by 137.8% during the second quarter. Algert Global LLC now owns 123,628 shares of the company’s stock valued at $4,742,000 after acquiring an additional 71,650 shares during the last quarter. Edgestream Partners L.P. boosted its stake in shares of Apellis Pharmaceuticals by 240.4% during the second quarter. Edgestream Partners L.P. now owns 54,572 shares of the company’s stock valued at $2,093,000 after acquiring an additional 38,541 shares during the last quarter. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of Apellis Pharmaceuticals during the third quarter valued at $1,370,000. 96.29% of the stock is owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Stock Performance

Shares of APLS stock opened at $33.21 on Friday. The stock’s 50-day moving average is $30.31 and its two-hundred day moving average is $34.58. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. Apellis Pharmaceuticals has a 1 year low of $24.34 and a 1 year high of $73.80. The firm has a market cap of $4.13 billion, a price-to-earnings ratio of -16.36 and a beta of 0.94.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm had revenue of $196.83 million for the quarter, compared to analysts’ expectations of $200.00 million. During the same quarter in the prior year, the business earned ($1.17) EPS. The company’s quarterly revenue was up 78.3% compared to the same quarter last year. Analysts predict that Apellis Pharmaceuticals will post -1.72 earnings per share for the current year.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).